Blind Patients READ Again — Blindness REVERSED!

Man lying in a hospital bed with monitors and IV equipment — Photo: Gorodenkoff / Shutterstock

A coin-sized chip implanted behind the retina is letting people blind from age-related eye disease read letters, numbers and words again, and European regulators just cleared it for sale.

Quick Take

The PRIMA retinal implant, made by California-based Science Corporation, received a CE mark, clearing it for commercial sale across 30 European countries.
In a 38-patient trial, 84% of participants regained the ability to read letters, numbers and words using restored central vision.
The device targets geographic atrophy, an advanced form of age-related macular degeneration with no prior treatment for central vision loss.
First commercial procedures are expected in Germany this September, with a US launch still years away.

What The PRIMA Implant Does And How It Works

Age-related macular degeneration destroys the light-sensing cells at the center of the retina, robbing people of the sharp vision needed to read a book or recognize a face. PRIMA is a two-millimeter photovoltaic chip surgically placed under the retina. It works with a pair of camera glasses that beam infrared light onto the chip, which converts that light into electrical pulses the brain can interpret as images.

The system does not replace natural sight. It creates a new, artificial signal in the damaged part of the eye while leaving whatever peripheral vision a patient still has completely untouched. Patients essentially learn to read again using a manufactured picture their brain has never seen before, a process that takes training and practice after surgery.

The Trial Results Behind The European Approval

The pivotal study, known as PRIMAvera, enrolled 38 patients across 17 clinical sites in five countries. Results published in the New England Journal of Medicine showed a mean improvement of 25.5 letters on a standard eye chart, more than five lines of vision, and one patient gained 59 letters, over eleven lines.

Eighty percent of patients achieved a clinically meaningful acuity gain at 12 months, a result the study reported as statistically significant. For a disease that had no treatment for central vision loss until now, those numbers explain why doctors and patients alike are calling this a milestone rather than just another incremental device update.

Science Corporation’s chief executive has framed the results as proof that direct neural stimulation can do what eye drops and injections never could for this disease. The company received its CE mark from the notified body DEKRA under European Union Medical Device Regulation, the formal clearance needed to sell a device commercially across the European Union.

From Lab To Living Rooms: The Path To Approval

The technology did not appear overnight. PRIMA began years ago under French company Pixium Vision, which won Food and Drug Administration (FDA) clearance to start a US feasibility study in patients with dry age-related macular degeneration. Science Corporation later acquired the program and pushed it through the larger European trial that led to this month’s approval.

The first commercial implant procedures are expected to begin in Germany in September 2026, according to European coverage of the approval. That timeline gives doctors and hospitals time to train surgical teams before the device reaches a wider patient population across the continent.

What Comes Next For American Patients

Americans hoping for quick access should temper expectations. The device is not yet approved for sale in the United States, and Science Corporation has said it is now pursuing that separate regulatory path with the FDA. Historically, FDA review of implantable neurological devices takes additional years beyond European clearance, even when trial data looks strong.

That gap matters for the millions of older Americans living with this disease, since age-related macular degeneration remains the leading cause of severe vision loss in people over 60 in developed countries. A treatment approved abroad offers hope, but it also raises fair questions about why American patients often wait longer for devices already helping people overseas.

Science Corp's PRIMA retinal implant just earned a CE mark: the first treatment shown to restore functional central vision in geographic atrophy. In the NEJM trial, 84% of patients could read again. Founded by Duke alum Max Hodak. pic.twitter.com/vFiG7abwOO

— Duke Capital Partners (@DukeCapPartners) July 27, 2026

A Note Of Caution Amid The Excitement

Independent reviewers point out this remains a single, small, open-label study without a control group, the kind of early evidence that can support approval while still leaving real questions about long-term durability and how well results hold up outside a research setting.

None of that undercuts what patients themselves are reporting: people who had no central vision are reading again. That is a genuinely rare kind of medical news, and it deserves to be treated with both enthusiasm and the patience good science requires before it reaches every American who could benefit from it.